|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:abusePotential
|
high
|
|
gptkbp:aroma
|
odorless
|
|
gptkbp:ATCCode
|
none
|
|
gptkbp:bannedIn
|
gptkb:Australia
gptkb:Canada
gptkb:New_Zealand
gptkb:United_Kingdom
gptkb:United_States
|
|
gptkbp:CASNumber
|
2759-28-6
|
|
gptkbp:chemicalFormula
|
C10H13N2
|
|
gptkbp:color
|
white
|
|
gptkbp:combines
|
gptkb:TFMPP
|
|
gptkbp:discoveredBy
|
1944
|
|
gptkbp:drugClass
|
stimulant
|
|
gptkbp:eliminationHalfLife
|
5.5 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:has_effect_similar_to
|
amphetamine
|
|
gptkbp:hasStreet
|
gptkb:Legal_E
gptkb:A2
Pep pills
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
BZP
|
|
gptkbp:IUPACName
|
gptkb:1-benzylpiperazine
|
|
gptkbp:legalStatus
|
gptkb:Class_C_(United_Kingdom)
gptkb:Schedule_III_(Canada)
gptkb:Schedule_I_(United_States)
illegal (New Zealand)
|
|
gptkbp:mechanismOfAction
|
serotonin-norepinephrine-dopamine releasing agent
|
|
gptkbp:meltingPoint
|
248–250 °C
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:molecularWeight
|
161.22 g/mol
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2105936
10343
9917
|
|
gptkbp:purpose
|
antineoplastic agent
|
|
gptkbp:recreational_use
|
party pill
|
|
gptkbp:relatedTo
|
gptkb:TFMPP
gptkb:mCPP
gptkb:MDMA
|
|
gptkbp:routeOfAdministration
|
oral
insufflation
|
|
gptkbp:sideEffect
|
nausea
anxiety
headache
insomnia
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:toxicity
|
can cause seizures at high doses
|
|
gptkbp:UNII
|
0VJ2P6OHDZ
|
|
gptkbp:bfsParent
|
gptkb:Belsize_Park_tube_station
gptkb:Belsize_Park_Underground_station
|
|
gptkbp:bfsLayer
|
6
|